BCL2 and prostate carcinoma: RT-PCR studies indicated that Myc, as well as BCL2, were significantly down regulated in PC3-AZD20 cells following treatment with CTA095 (Figure 12B), indicating that this down regulation may contribute to the induction of apoptosis in Src inhibitor resistant prostate cancer cells.